Lercanidipine Accord (Lercanidipine Hydrochloride)

Lercanidipine works by selectively blocking L‑type calcium channels on vascular smooth‑muscle cells. This inhibition prevents calcium entry, leading to relaxation of arterial smooth muscle, vasodilation, and a subsequent decrease in peripheral vascular resistance. The resulting effect is a reduction in systemic blood pressure without significant impact on cardiac conduction.

The appropriate dose of Lercanidipine Accord is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Physicians typically start with a low dose and may titrate upward to achieve target blood‑pressure goals, following local prescribing guidelines.

Safety data for lercanidipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lercanidipine Accord, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine is a third‑generation dihydropyridine calcium channel blocker, offering a gradual onset and long duration of action, which can reduce the incidence of reflex tachycardia compared with older agents like nifedipine. Compared with amlodipine, lercanidipine may have a slightly lower risk of peripheral edema, though individual response varies.

Lercanidipine Accord tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Lercanidipine Accord is taken orally, usually once daily with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise instructed by the prescriber.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, and allergic reactions such as angioedema or rash. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, sudden swelling of the face or throat, or unexplained liver-related signs.

Lercanidipine Accord should be avoided in patients with known hypersensitivity to lercanidipine or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors without appropriate dose adjustment. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.